All the Drug Class Drugs
Antimetabolite. Nelarabine 5 mg/ml. VIALS: 6 x 50 ml x 250 mg/vial. Only
under vis. of physician experienced in
cytotox. agents. Adults and adolesc.
(16 yrs and older): 1,500 mg/m2 I.V.
over 2 hrs on days 1, 3 and 5. Repeat
every 21 days. Child and adolesc. (21
yrs and younger): 650 mg/m2 I.V. over 1
hr. dly for 5 consec. days. Rpt. aft. 21
Tmt. T-ALL, T-LBL whose dis. not respond./
relapsed foll. tmt. with at least 2
chemother. regimens. Informat. based on
limited data due to small pt. populat.
Antimetabolite. Azacitidine 100 mg. VIAL (Lyophilized pwdr. for suspens. for SC Inj./sol. for infus.): 1. 1st tmt. cycle, for all pts. regardless of baseline hematology lab. values, is 75 mg/m² SC or IV, daily for 7 d. Premedicate pts. for nausea & vomit.
Obtain complete blood counts, hep. enzym., serum creatinine prior to the 1st dose.
Subseq. Tmt. Cycles: Repeat cycles every 4 wks. The dose may be incr. to 100 mg/m² if no beneficial effect is seen after 2 tmt. cycles and if no toxicity other than nausea & vomit. has occurred. It is recomm. that pts. be treated for a min. of 4-6 cycles. However, complete or partial response may require addit. tmt. cycles. Tmt. may be continued as long as the pt. continues to benefit.
Tmt. of pts. with the following French-American-British (FAB) myelodysplastic syndr. subtypes: refract. anemia (RA) or refract. anemia with ringed sideroblasts (if accompan. by neutrop. or thrombocytop. or require. transfusions), refract. anemia with excess blasts (RAEB), refract. anemia with excess blasts in transformation (RAEB-T), and chron. myelomonocytic leukem. (CMMoL).
C/I: Hypersens. Pts. with advanced malig. hep. tumors.
Antimetabolite. Capecitabine 500 mg. F.C. TABS.: 30, 60, 120. Dosage must be ajust. individ. accord. to pt. medical cond.
Adjuvant Colon Cancer: of pts. follow. surgery of stage III (Dukes stage C) colon cancer. Tmt. of pts. with advanced or metast. colorect. cancer. 1st line tmt. of advanced gastric cancer in comb. with
chemother. In comb. with docetaxel is indic. for the tmt. of pts. with metast. breast cancer after fail.of prior anthracyclinecontain. chemother. Capecitabine is also indicated for the tmt. of advanced or metast. breast cancer after fail. of standard ther. includ. a taxane unless therapy with a taxane is clinical. contraind.
C/I: Hypersens., history of severe and unexpected reac. to fluoropyrimidine ther., Hypersens to fluorouracil. In pts. with known DPD defic. Preg., lact. Sev. leucopenia, neutropenia, or thrombocytopenia. Sev. hep.impair. Sev. renal impair. (CrCl< 30 ml/min). Tmt. with sorivudine or its chem. related analogues, such as brivudine. If contraind. exist to any of the med. products in the comb.regimen, that med. product should not be used.
Antimetabolite. Methotrexate 2.5 mg, 100 mg. TABS.: 50 x 2.5 mg. 1 tab 3 x per wk. 1hr
bef. food or 11/2-2 hrs. aft. See lit.
VIAL.: 5 ml, 10 ml, 50 ml ×100 mg/ml. I.M/I.V. Dosage must be ajust. individ. accord. indicat., gen. cond., blood counts.
Antineop. chemother.: tmt. of gestat.
destruents and hydatidiform mole.
Palliation of acute lymphoc. leukemia.
Tmt. & prophylax. of meningeal
leukemia. Greatest effect has been
observed in palliation of acute lymphobl.
(stem cell) leukemias in child. In comb.
with other anticancer agents,
Induct. of remiss., but is most commonly
used in mainten. of induced remiss.
Abitrexate may be used alone or in comb.
with other antineopl. in the manag. of
breast cancer, epidermoid cancers of the
head &neck, lung cancer (particularly
squamous cell and small cell types),
bladder cancer and osteogeny. cancer.
Tmt. of the advanced stages (III and IV
Peter’s Staging Syst.) of lymphosarcoma,
particul. in child. , and in advanced cases
of mycosis fungoides.
Psoriasis: symptom. control of severe
recalcitrant, disabling psoriasis which is
not adequ. respons. to other forms of
ther., and only when the diagnosis has
been established, as by biopsy and/or
after dermatology. consultation.
RA: Tmt. of selected adults with severe
RA, only when the diagnosis has been
well established accord. to rheumatolog,
standards, with inadeq. response to other
forms of antirheumatic ther., includ. full
dose NSAIDs and usual. a trial of at least
one or more dis.-modif. antirheumatic
C/I: Hypersens. Hep. insuffic. Alcohol
abuse. Renal insuffic. CrCl less than 20
ml/min. Pre-exist. blood dyscrasias, e.g.
bone marrow hypoplasia, leukopenia,
thrombocytopenia, or significant
anaemia. Serious, acute/ chron. infect.
such as tuberculosis , HIV. Ulcers of the
oral cavity and known active GI ulcer dis. Preg. Lact. Concur. vaccin. with live